We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CBK:XETRCommerzbank AG Analysis

Data as of 2026-07-15 - not real-time

$32.81

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

CBK is trading at $32.81, comfortably above its 20‑day SMA of 32.30 and 50‑day SMA of 30.40, indicating a short‑term bullish bias. The price sits near the identified support level of $30.48, providing a cushion against downside, while the 52‑week high of $34.45 serves as near‑term resistance. Technical momentum is mixed: RSI at 61 suggests the stock is not yet overbought, but the MACD histogram is slightly negative and the signal line is labeled bearish, hinting at possible short‑term weakness. Volatility over the past 30 days is about 22%, higher than typical for a low‑beta (0.33) regional bank, implying modest price swings. Fundamentally, the forward PE of 10.4 and trailing PE of 11.97 are well below the industry average of 17.79, and the DCF fair value of $35.46 offers roughly a 3.6% upside.
The balance sheet shows ample liquidity with $182.9 M cash against $132.8 M debt and a negligible payout ratio of 3.6%, supporting dividend sustainability. Profitability metrics are solid – operating margin of 55% and ROE of 14.6% – and revenue is growing at 5.3% YoY. The current dividend yield of 0.6% complements the low payout, offering a modest income stream while preserving capital for growth. Given the modest beta and low geographic concentration (U.S. only), systematic risk is limited, though regulatory and sector risks remain medium for regional banks. Overall, the stock appears undervalued with a defensive dividend and a modest upside potential, making it attractive for investors with a medium‑to‑long horizon.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Price above 20‑day and 50‑day SMAs
  • Support level at $30.48 provides downside cushion
  • Undervalued valuation with DCF fair value above market

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Limited upside to resistance at $34.45
  • Strong earnings and low PE relative to peers
  • Stable cash position supports dividend

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervalued relative to industry PE
  • Low beta and defensive banking model
  • Sustainable dividend with low payout ratio

Key Metrics & Analysis

Financial Health

Revenue Growth5.30%
Profit Margin41.77%
P/E Ratio12.0
ROE14.64%
ROA1.65%
P/B Ratio1.5
Op. Cash Flow$38.4M
Industry P/E17.8

Technical Analysis

TrendBullish
RSI61.0
Support$30.48
Resistance$34.45
MA 20$32.30
MA 50$30.40
MA 200$26.79
MACDBearish
VolumeDecreasing
Fear & Greed Index92.36

Valuation

Fair Value$35.46
Target Price$34.00
Upside/Downside3.63%
GradeUndervalued
TypeValue
Dividend Yield0.60%

Risk Assessment

Beta0.33
Volatility22.02%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.